%PDF-1.4
%
38 0 obj
<>
endobj
35 0 obj
<>
endobj
115 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-12-14T19:56:50Z
2024-03-29T04:48:09-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T04:48:09-07:00
application/pdf
Heather
2001-924.dec02
uuid:ff604d04-1dd1-11b2-0a00-4b0827edca00
uuid:ff604d06-1dd1-11b2-0a00-380000000000
endstream
endobj
24 0 obj
<>
endobj
25 0 obj
<>
endobj
39 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
17 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
130 0 obj
[134 0 R]
endobj
131 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(Adams, )Tj
/TT1 1 Tf
0 Tc 0.03889 Tw 3.3714 0 Td
(et al)Tj
/TT0 1 Tf
-0.00011 Tc 2.0772 0 Td
[(and Lussier)39.7 (, )]TJ
/TT1 1 Tf
0 Tc [-0.2 (et al)]TJ
/TT0 1 Tf
7.2521 0 Td
[(also found no dif)17.8 (ferences in)]TJ
0.2509 Tw -12.7008 -1.2 Td
(improvement outcome in patients who had postinjection)Tj
-0.00011 Tc 0 Tw 0 -1.2 TD
(flares)Tj
0 Tc 6.5 0 0 6.5 76.1997 692.4615 Tm
(4,6)Tj
0.00929 Tw 10 0 0 10 84.3246 689.1616 Tm
[(. Joint aspiration and culture of synovial ef)17.8 (fusions is)]TJ
0.2153 Tw -3.0325 -1.2 Td
(an essential step in excluding iatrogenic joint infections.)Tj
0.10831 Tw T*
(When infection has been excluded, conservative treatment)Tj
-0.02229 Tw T*
(with rest, ice, NSAID, and occasionally corticosteroid injec-)Tj
0.0249 Tw T*
[(tions is very ef)17.8 (fective in managing the acute problem.)]TJ
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(REFERENCES)Tj
/TT0 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 61 607.1616 Tm
[(1.)-875 (Peyron JG. )17.7 (V)60.1 (iscosupplementation for the treatment of osteoarthritis)]TJ
1.675 -1.25 Td
(of the knee with hyaluronan and hylan: rationale and state of the)Tj
-0.00011 Tc 0 -1.25 TD
[(art. In: )17.7 (T)69.7 (anaka S, Hamanishic G, editors. )54.8 (Advances in osteoarthritis.)]TJ
0 Tc T*
[(T)69.8 (okyo: Springer )17.7 (V)111.1 (erlag; 1999:213-36.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (Brandt KD, Smith GN, Simon LS. Intra-articular injection of)]TJ
0 Tc 1.675 -1.25 Td
(hyaluronan as treatment for knee osteoarthritis \227 what is the)Tj
T*
[(evidence? )54.9 (Arthritis Rheum 2000;43:1)36.8 (192-203.)]TJ
-1.675 -1.25 Td
[(3.)-875 (Altman RD, Moskowitz R, and the Hyalgan Study Group.)]TJ
1.675 -1.25 Td
(Intra-articular sodium hyaluronate \(Hyalgan\) in the treatment of)Tj
T*
(patients with osteoarthritis of the knee: a randomized clinical trial. )Tj
T*
(J Rheumatol 1998;25:2203-12.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Lussier )54.8 (A, Civido )54.8 (AA, McFarlane CA, Olszynski )17.7 (WP)110.7 (, Potashner)]TJ
0 Tc 1.675 -1.25 Td
[(WJ, De Medicis R. )17.7 (V)60.1 (iscosupplementation with hylan for the)]TJ
T*
(treatment of osteoarthritis: findings from clinical practice in)Tj
T*
(Canada. J Rheumatol 1996;23:1579-85.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(5.)-875.1 (Adams ME, )54.8 (Atkinson MH, Lussier )54.8 (AJ, et al. )17.7 (The role of )]TJ
0 Tc 1.675 -1.25 Td
(viscosupplementation with hylan G\226F 20 \(Synvisc\) in the treatment)Tj
T*
(of osteoarthritis of the knee: a Canadian multicenter trial comparing)Tj
T*
(hylan G-F alone, hylan G-F 20 with non steroidal )Tj
-0.00011 Tc T*
(anti-inflammatory drugs \(NSAIDs\) and NSAIDs alone.)Tj
0 Tc T*
(Osteoarthritis Cartilage 1995;3:213-26.)Tj
-0.00011 Tc 31.325 38.421 Td
[(6.)-875.1 (Adams ME. )54.8 (An analysis of clinical studies of the use of crosslinked)]TJ
0 Tc 1.675 -1.25 Td
(hyaluronan, hylan, in the treatment of osteoarthritis. J Rheumatol)Tj
T*
(1993;20 Suppl 39:16-8.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(7.)-875.1 (Puttick MPE, )17.7 (W)79.7 (ade JP)110.8 (, Chalmers )54.8 (A, Connell DG, Rango KK. )54.8 (Acute)]TJ
1.675 -1.25 Td
(local reactions after intra-articular hylan for osteoarthritis of the)Tj
0 Tc T*
[(knee. J Rheumatol 1995;22:131)36.9 (1-4.)]TJ
-1.675 -1.25 Td
[(8. )-600 (W)79.8 (emple MA, Starkebaw MG. Simultaneous pseudogout and gout)]TJ
1.675 -1.25 Td
(after intra-articular injection of hylan gel fluid 20. J Clin)Tj
T*
(Rheumatol 2000;6:58-9.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Maillefert JF)79.7 (, Hirschhorn P)110.7 (, Pascaud F)79.7 (,)-0.1 ( Piroth C, )17.7 (T)69.7 (avernier C. )54.8 (Acute)]TJ
0 Tc 1.675 -1.25 Td
(attack of chondrocalcinosis after an intra-articular injection of)Tj
T*
(hyaluronan. Rev Rhum \(Engl Ed\) 1997;10:593-4.)Tj
-2.175 -1.25 Td
[(10.)-875 (Luzar MJ. Pseudogout following the intra-articular injection of)]TJ
2.175 -1.25 Td
[(sodium hyaluronate. )54.9 (Arthritis Rheum 1998;5:939-40.)]TJ
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Moreland L)73.9 (W)91.7 (, )54.8 (Arnold )17.7 (WJ, Saway )54.8 (A, Savory C, Sikes D. Ef)17.7 (ficacy)]TJ
2.1381 -1.25 Td
(and safety of intra-articular hylan G-F 20 \(Synvisc\), a viscoelastic)Tj
0 Tc T*
(derivative of hyaluronan, in patients with osteoarthritis of the knee)Tj
T*
[([abstract]. )54.9 (Arthritis Rheum 1993;36 Suppl:B143.)]TJ
-2.175 -1.25 Td
[(12.)-875 (W)79.8 (obig M, Beks P)110.8 (, Diokhut )54.8 (A, Maier R, )17.7 (V)111.1 (etter G. Open label )]TJ
2.175 -1.25 Td
[(multicenter trial of the safety and ef)17.8 (ficacy of viscosupplementation)]TJ
-0.00011 Tc T*
(with hylan G-F \(Synvisc\) in primary osteoarthritis of the knee. )Tj
0 Tc T*
(J Clin Rheumatol 1999;5:524-31. )Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875.1 (Allen E, Krohn K. )54.8 (Adverse reaction to hylan GF-20 [letter]. )]TJ
0 Tc 2.175 -1.25 Td
(J Rheumatol 2000;27:1572.)Tj
-0.00011 Tc -0.0298 Tw -2.175 -1.25 Td
[(14.)-875.1 (Listrat )-37.1 (V)129 (,)-0.1 ( A)91.9 (yrad A, )-54.8 (Patarnello )-54.8 (F)79.7 (,)-0.1 ( )-54.9 (et )-54.9 (al. Arthroscopic )-54.9 (evaluation )-54.8 (of)]TJ
0 Tc 0.02499 Tw 2.175 -1.25 Td
(potential structure modifying activity of hyaluronan \(Hyalgan\) in)Tj
T*
(osteoarthritis of the knee. Osteoarthritis Cartilage 1997;5:153-60.)Tj
-2.175 -1.25 Td
[(15.)-875 (Daumen-Legre )17.7 (V)129.1 (, Pham )17.7 (T)74 (, )54.8 (Acquaviva PC, Laf)17.8 (for)17.8 (gue P)110.8 (. Evaluation)]TJ
2.175 -1.25 Td
[(of safety and ef)17.8 (ficacy of viscosupplementation in knee)]TJ
-0.00011 Tc T*
[(osteoarthritis with chondrocalcinosis [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(1999;42 Suppl 9:528.)Tj
ET
/CS0 CS 0 0 0 1 SCN
54 54 m
558 54 l
S
BT
/TT1 1 Tf
8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2002; 29:12)Tj
0 Tw -45.7952 -0.0313 Td
(2614)Tj
ET
0 0 0 0 scn
/GS0 gs
102.25 59.08 407.5 -10.83 re
f*
0.5 w
102.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
83 0 obj
<>
endobj
121 0 obj
<>
endobj
46 0 obj
<>
endobj
41 0 obj
<>
endobj
51 0 obj
<>
endobj
50 0 obj
<>
endobj
76 0 obj
<>stream
HdVpTs͋рlbHvd IAg]v4hy1TwÀD" 錈`
*j;
Ha"f2c}M+h"
5uosw
`ٿW:!
'Jon%@ꗷyt%,_S--w~g u%MiyZpx3~B{1sU3[}@-+f̌%Ky40̈
->2֥m팛Op>o]ؚ8Ȧ̃V3
"gA>#k$LO^[}c/ r%pLETjX|+MXЂH{M`&뱓gs}R)$߅@=(Ba75GO1b
":܌Z|
OtkfN0q̠O&J6I6ޑ!vϹg4*h6lËEBJetQL_<#A5A-U{[JIv5y{%R-ItYUkය[hk=Kxq'%Q]Fj-um37
s
ݏ=;>q9|)qR&JH;d2jCu^#xxNw?tcUFak<#bs\FZWYw8-ʥtd\)IU̫FSbRJncɄ*:2w2M`YIx[j6VzqOx|qgЇ!3VȖ84YB2T,ifiUII/˫#rZ(-5]yNW50N3dg~b[:!kwZf?|Jt;]nuK0,dKC;$k'+q0~}B31,8I^G+0yilr'i<&Od''9ǤO3f}FPUJ|K"VsB뤳0c1߸01v0&jl`Y3zú:lNLJߐ9$RT'{ j&i*Y!uW[+Y5NVJأ*cg!~+&~5xsRj|庽vͭ7sS߹^T"/4/@Q#_:lh%\4dp̌44$jWΨcg >@sU^cB5~JjkJ*KQnN
uzu?kNh,BsClFVEFaw6hoGNΌh=&,
82^;ISun
}K6nX/18FQ11p; ߏ~.CGW;+Y3ۘjfGV&bOfhG$dasq5ܚ:]7/m%}+XkuJ2랤Wyz>Z5|]D{g2L_9kXrfɜ9r-(%$8[hVD<Ń!f =|wZ2V>ypϙ/m
<dzRʗ0s_qٽMD(OʈڇgLm[ՃbUD0*1{ |ϊQ;zoa:4xqv"O9?ݻ3]0n4xPM6N+F9vwyųgpH;vKX|%5մ7c8T
:|>ϴq̭zO[br%
\,W?RG|H($)}vlֱSQ=;QϨϢOCϹ7kɻf=z5mSgZ=IwJ_)6aڽӋrcάo8ߝ̚0~ōĆ1&U.9;ĵ0mŀhTBukC$jD PҦ*)
jTm㤭,<ͮURu}fvonG#݀4rH'@!C#9 4<`F4`^M#{ Fpy`nE# ft Ly@4~
Ζpv >GHE4&I#l_/О"OL y쫺5Gtr/'0
Ք4+H!ڐt;[Nv Wۄ7ڄ3m66M_tۤ۰T"Dh/%LGpn3tqa<.^
qaM\ƅ
~vE+t+);ssKBc@p;sYv9yDpDY#H8Yu ($j4w5 LM 0H^7p+a[Mx{CUta~JU\5UcmU\Tl[\PySF*
M UoA%~H{DY5Qح&Q4cz
ۡ}dkۊzuԫĭz{37V=<5ÚR5W֪
Z!H[}+wzDl/F+lx)aKA!]M5tO%64+ȃ3AT";g.`<U:@*dgdޣ*l-Yv"d7"A g8QoCUJ脔O?h=fEv
}Or_*.z-4N}Y$ 5*kf,;+R!2(vo69߅~/Hhwȸ_N%y͠[>qn15;K7ӖtjI1ˣ\Zam;5SۍmVcbavUoo[Y$Ý+9t!DPiJK=|ATcIϒVDFs)Utm\W287E>yfwkS |!Ud5f&|T]#݈'r ~({<e7(;C鞺=zn{D4Irhv윮$zMjᩃWZ,]\9iy/0kU9+$3>U2K簣()&U!vo#U+}2]IPddߔ˺lr_XP.c$ H2Ȭv$2jg2x)tnE2&˺*Ձ[
:+yyyZ+zx<~o`qJgq*_=!3=rs{9b 볤[tD4쒳^fϊMeXlO#Ͳ- DF3:9Q'ީ7R^>Q>$# ,NLNC6됹`AqI39 ^f ;v%[zѳ?qLNݸpcEx6qq{;_{s|1C\
ZZ8x -PJSl
(TXjMP7Rjm7(NQ
iVcsNZǴ?|_